Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Drinking Water: The Saltier The Better?

Bispham NZ, Nowak KL.

J Am Heart Assoc. 2019 May 7;8(9):e012758. doi: 10.1161/JAHA.119.012758.

2.

IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD.

Hung AM, Tsuchida Y, Nowak KL, Sarkar S, Chonchol M, Whitfield V, Salas N, Dikalova A, Yancey PG, Huang J, Linton MF, Ikizler TA, Kon V.

Clin J Am Soc Nephrol. 2019 May 7;14(5):702-711. doi: 10.2215/CJN.04360418. Epub 2019 Apr 23.

PMID:
31015261
3.

Serum Sodium and Pulse Pressure in SPRINT.

Nowak KL, Chonchol M, Jovanovich A, You Z, Bates J, Foy C, Glasser S, Killeen AA, Kostis J, Rodriguez CJ, Segal M, Simmons DL, Taylor A, Lovato LC, Ambrosius WT, Supiano MA; SPRINT Research Group.

Am J Hypertens. 2019 Jun 11;32(7):649-656. doi: 10.1093/ajh/hpz055.

PMID:
30977767
4.

Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Nowak KL, Gitomer B, Farmer-Bailey H, Wang W, Malaczewski M, Klawitter J, You Z, George D, Patel N, Jovanovich A, Chonchol M.

Am J Kidney Dis. 2019 Feb 22. pii: S0272-6386(19)30079-4. doi: 10.1053/j.ajkd.2018.12.037. [Epub ahead of print]

PMID:
30803706
5.

Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.

Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M, Kendrick J, Jalal D.

PLoS One. 2018 Oct 24;13(10):e0205831. doi: 10.1371/journal.pone.0205831. eCollection 2018.

6.

Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1493-1501. doi: 10.2215/CJN.05850518. Epub 2018 Sep 18.

PMID:
30228110
7.

Does inflammation affect outcomes in dialysis patients?

Nowak KL, Chonchol M.

Semin Dial. 2018 Jul;31(4):388-397. doi: 10.1111/sdi.12686. Epub 2018 Mar 7. Review.

PMID:
29513906
8.

Serum Sodium and Cognition in Older Community-Dwelling Men.

Nowak KL, Yaffe K, Orwoll ES, Ix JH, You Z, Barrett-Connor E, Hoffman AR, Chonchol M.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):366-374. doi: 10.2215/CJN.07400717. Epub 2018 Feb 8.

9.

Dietary Sodium/Potassium Intake Does Not Affect Cognitive Function or Brain Imaging Indices.

Nowak KL, Fried L, Jovanovich A, Ix J, Yaffe K, You Z, Chonchol M.

Am J Nephrol. 2018;47(1):57-65. doi: 10.1159/000486580. Epub 2018 Jan 24.

10.

Strategies for Achieving Healthy Vascular Aging.

Nowak KL, Rossman MJ, Chonchol M, Seals DR.

Hypertension. 2018 Mar;71(3):389-402. doi: 10.1161/HYPERTENSIONAHA.117.10439. Epub 2018 Jan 8. Review. No abstract available.

11.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

12.

Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study
.

Nowak KL, Chonchol M, You Z, Gupta M, Gitomer B.

Clin Nephrol. 2018 Mar;89(3):196-204. doi: 10.5414/CN109247.

13.

Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial.

Kendrick J, Andrews E, You Z, Moreau K, Nowak KL, Farmer-Bailey H, Seals DR, Chonchol M.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1438-1446. doi: 10.2215/CJN.01870217. Epub 2017 Aug 7.

14.

A guiding map for inflammation.

Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA.

Nat Immunol. 2017 Jul 19;18(8):826-831. doi: 10.1038/ni.3790.

15.

Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function
.

Nowak KL, Hung A, Ikizler TA, Farmer-Bailey H, Salas-Cruz N, Sarkar S, Hoofnagle A, You Z, Chonchol M.

Clin Nephrol. 2017 Sep;88(9):132-143. doi: 10.5414/CN109122.

PMID:
28699886
16.

Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.

Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M.

Nephrol Dial Transplant. 2017 Feb 1;32(2):342-347. doi: 10.1093/ndt/gfw013.

17.

Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults.

Nowak KL, Bartz TM, Dalrymple L, de Boer IH, Kestenbaum B, Shlipak MG, Garimella PS, Ix JH, Chonchol M.

J Am Soc Nephrol. 2017 Apr;28(4):1239-1246. doi: 10.1681/ASN.2016040401. Epub 2016 Nov 10.

18.

IL-1 Inhibition and Vascular Function in CKD.

Nowak KL, Chonchol M, Ikizler TA, Farmer-Bailey H, Salas N, Chaudhry R, Wang W, Smits G, Tengesdal I, Dinarello CA, Hung AM.

J Am Soc Nephrol. 2017 Mar;28(3):971-980. doi: 10.1681/ASN.2016040453. Epub 2016 Sep 19.

19.

Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Jalal DI, Decker E, Perrenoud L, Nowak KL, Bispham N, Mehta T, Smits G, You Z, Seals D, Chonchol M, Johnson RJ.

J Am Soc Nephrol. 2017 Mar;28(3):943-952. doi: 10.1681/ASN.2016050521. Epub 2016 Sep 12.

20.

Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B.

Am J Nephrol. 2016;44(3):171-8. doi: 10.1159/000448695. Epub 2016 Aug 23.

21.
22.

Pharmacological manipulation of CB1 receptor function alters development of tolerance to alcohol.

Nowak KL, Vinod KY, Hungund BL.

Alcohol Alcohol. 2006 Jan-Feb;41(1):24-32. Epub 2005 Oct 10.

PMID:
16216824
23.
24.

An assessment of novelty-seeking behavior in alcohol-preferring and nonpreferring rats.

Nowak KL, Ingraham CM, Mckinzie DL, Mcbride WJ, Lumeng L, Li TK, Murphy JM.

Pharmacol Biochem Behav. 2000 May;66(1):113-21.

PMID:
10837850
25.

Involvement of dopamine D2 autoreceptors in the ventral tegmental area on alcohol and saccharin intake of the alcohol-preferring P rat.

Nowak KL, McBride WJ, Lumeng L, Li TK, Murphy JM.

Alcohol Clin Exp Res. 2000 Apr;24(4):476-83.

PMID:
10798583
26.

Patterns of ethanol and saccharin intake in P rats under limited-access conditions.

Nowak KL, McKinzie DL, McBride WJ, Murphy JM.

Alcohol. 1999 Aug;19(1):85-96.

PMID:
10487392
27.

Development of alcohol drinking behavior in rat lines selectively bred for divergent alcohol preference.

McKinzie DL, Nowak KL, Murphy JM, Li TK, Lumeng L, McBride WJ.

Alcohol Clin Exp Res. 1998 Oct;22(7):1584-90.

PMID:
9802545
28.

Blocking GABA(A) receptors in the anterior ventral tegmental area attenuates ethanol intake of the alcohol-preferring P rat.

Nowak KL, McBride WJ, Lumeng L, Li TK, Murphy JM.

Psychopharmacology (Berl). 1998 Sep;139(1-2):108-16.

PMID:
9768548
29.

The alcohol deprivation effect in the alcohol-preferring P rat under free-drinking and operant access conditions.

McKinzie DL, Nowak KL, Yorger L, McBride WJ, Murphy JM, Lumeng L, Li TK.

Alcohol Clin Exp Res. 1998 Aug;22(5):1170-6.

PMID:
9726292

Supplemental Content

Loading ...
Support Center